The application of plant growth-promoting rhizobacteria (PGPR) in the field has been hampered by a number of gaps in the knowledge of the mechanisms that improve plant growth, health, and production. These gaps include (i) the ability of PGPR to colonize the rhizosphere of plants and (ii) the ability of bacterial strains to thrive under different environmental conditions. In this review, different strategies of PGPR to colonize the rhizosphere of host plants are summarized and the advantages of having highly competitive strains are discussed. Some mechanisms exhibited by PGPR to colonize the rhizosphere include recognition of chemical signals and nutrients from root exudates, antioxidant activities, biofilm production, bacterial motility, as well as efficient evasion and suppression of the plant immune system. Moreover, many PGPR contain secretion systems and produce antimicrobial compounds, such as antibiotics, volatile organic compounds, and lytic enzymes that enable them to restrict the growth of potentially phytopathogenic microorganisms. Finally, the ability of PGPR to compete and successfully colonize the rhizosphere should be considered in the development and application of bioinoculants.
Fifteen (15) backyard farms were investigated to determine the antimicrobial susceptibility and invasion ability of S. aureus isolates from cows with subclinical mastitis in México. A total of 106 cows were sampled and 31 S. aureus isolates were recovered. S. aureus isolates were resistant to penicillin class antibiotics and susceptible to gentamicin and cetyltrimethylammonium bromide. STA9 and STA13 isolates were resistant to erythromycin (MIC > 25 microg/ml) and lincomycin (STA13, MIC > 25 microg/ml; STA9, MIC > 100 microg/ml). STA9 isolate harbors the erm(B) and msr(A) genes, whereas STA13 isolate harbors the erm(C) gene. STA9 and STA13 isolates contains the lnu(A) gene. Only 5 isolates (STA11, STA13, STA14, STA15 and STA21) were able to internalize in bovine mammary epithelial cells. These results indicate that S. aureus isolates from dairy backyard farms showed differences in the antimicrobial susceptibility patterns and invasion ability in bovine mammary epithelial cells. This kind of evaluations should be performed in different dairy regions, since resistance patterns and isolate diversity vary on a per-region basis.
Three pathogenic fungi of blueberry (Vaccinium spp.) responsible for dieback disease, identified as Pestalotiopsis clavispora, Colletotrichum gloeosporioides and Lasiodiplodia pseudotheobromae, were isolated in the northwestern region of the state of Michoacán, Mexico. The mycelial growth in vitro of these fungi was inhibited by extracts from Lantana hirta, Argemone ochroleuca and Adenophyllum porophyllum, medicinal plants collected in Sahuayo, Michoacán, Mexico. The extracts showed different degrees of inhibition; the most effective were: M5L extract from L. hirta and M6LFr extract from A. ochroleuca, both of which inhibited 100% of the mycelial growth of P. clavispora and C. gloeosporioides; and M4LS extract from A. porophyllum, which inhibited 100% of the mycelial growth of the three pathogens. The extracts were fractionated by thin layer and column chromatography, and the most active fractions were analyzed by gas chromatography-mass spectrometry. The major compounds identified in L. hirta extract were Phytol and α-Sitosterol. The compounds identified in A. ochroleuca were Toluene and Benzene, 1,3-bis(3-phenoxyphenoxy)-. In A. porophyllum, the compound identified was Hexanedioic acid, bis(2-ethylhexyl) ester. These results show the potential of L. hirta, A. ochroleuca and A. porophyllum as a source of antifungal compounds.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.